Misuse of Drugs Act 1973 (Amendment of First and Third Schedules) Order 2022

Status:

Published in Subsidiary Legislation Supplement
on 31 May 2022

No. S 440

Misuse of Drugs Act 1973

Misuse of Drugs Act 1973
(Amendment of First and
Third Schedules) Order 2022

In exercise of the powers conferred by section 59 of the Misuse of Drugs Act 1973, the Minister for Home Affairs makes the following Order:

Citation and commencement

1. This Order is the Misuse of Drugs Act 1973 (Amendment of First and Third Schedules) Order 2022 and comes into operation on 1 June 2022.

Amendment of First Schedule

2. In Part 1 of the First Schedule to the Misuse of Drugs Act 1973 —

(a)

in paragraph 16, after item (6), insert —

“(6A)

1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 3,4-Methylenedioxy-α-pyrrolidinohexanophenone or 3,4-MDPHP)”;

(b)

in paragraph 16, after item (8AA), insert —

“(8AAAA)

2-(Butylamino)-1-phenylhexan-1-one (also known as N-Butylhexedrone or α‑Butylaminohexanophenone)”;

(c)

in paragraph 18, after item (1), insert —

“(1A)

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1H-indazole-3-carboxamide (also known as ADB-5-Bromo-INACA) and its bromo positional isomers in the 6‑membered ring of the indazole structure”;

(d)

in paragraph 18, after item (16), insert —

“(16A)

1-(1-(1-(4-Bromophenyl)ethyl)-piperidin-4-yl)-1,3-dihydro-2H-imidazol-2-one (also known as Brorphine) and its bromo positional isomers in the phenyl ring”;

(e)

in paragraph 18, after item (23), insert —

“(23A)

2-(1-(Cyclohexylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’‑(1-(Cyclohexylmethyl)-2-oxoindolin-3-ylidene)benzohydrazide or BZO-CHMOXIZID)”;

(f)

in paragraph 18, after item (30), insert —

“(30A)

N,N-Diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as Metonitazene) and its diethylamino structural isomers and their respective methoxy positional isomers in the phenyl ring and nitro positional isomers in the 6‑membered ring of the benzimidazole structure”;

(g)

in paragraph 18, after item (43), insert —

“(43A)

N-Ethyl-1-(3-fluorophenyl)propan-2-amine (also known as 3‑Fluoroethamphetamine, 3‑Fluoroethylamphetamine or 3‑FEA) and its fluoro positional isomers in the phenyl ring”;

(h)

in paragraph 18, after item (45), insert —

“(45A)

2-(2-(1-(4-Fluorobenzyl)-1H-(6-hydroxyindol)-3-yl)acetamido)-3,3-dimethylbutanamide and its N‑(1‑amino-1-oxohexan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring and hydroxy positional isomers in the 6‑membered ring of the indole structure

(45B)

2-(2-(1-(4-Fluorobenzyl)-1H-indol-3-yl)acetamido)-3,3-dimethylbutanamide (also known as ADB‑FUBIATA or FUB-ACADB or AD-18) and its N‑(1‑amino-1-oxohexan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring”;

(i)

in paragraph 18, after item (47), insert —

“(47A)

2-(1-(5-Fluoropentyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’‑(1‑(5‑Fluoropentyl)-2-oxoindolin-3-ylidene)benzohydrazide or 5-Fluoro-BZO-POXIZID or 5F‑BZO‑POXIZID or MDA‑19 5-fluoropentyl analogue or 5F‑MDA‑19) and its fluoro positional isomers in the pentyl group”;

(j)

in paragraph 18, after item (51), insert —

“(51A)

2-(1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’‑(1‑Hexyl‑2‑oxoindolin‑3-ylidene)benzohydrazide or BZO‑HEXOXIZID or MDA-19)”;

(k)

in paragraph 18, after item (54), insert —

“(54A)

2-(1-(5-Hydroxyhexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’‑(1‑(5‑Hydroxyhexyl)-2-oxoindolin-3-ylidene)benzohydrazide) and its hydroxy positional isomers in the hexyl group”;

(l)

in paragraph 18, after item (56), insert —

“(56A)

2-(1-(5-Hydroxypentyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’‑(1‑(5‑Hydroxypentyl)-2-oxoindolin-3-ylidene)benzohydrazide) and its hydroxy positional isomers in the pentyl group”;

(m)

in paragraph 18, after item (75), insert —

“(75A)

2-(1-Pentyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’‑(1‑Pentyl‑2‑oxoindolin-3-ylidene)benzohydrazide or BZO‑POXIZID or MDA-19 pentyl analogue or 5C‑MDA‑19)”;

(n)

in paragraph 18, after item (76), insert —

“(76A)

1-Phenyl-2-phenyl-2-(1-pyrrolidinyl)ethanone (also known as α-Pyrrolidino-2-phenylacetophenone or α‑D2PV)”;

(o)

in paragraph 20, after item (50), insert —

“(51)

(1-(Pent-4-en-1-yl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (also known as XLR-11 N-(4-pentenyl) analogue or UR-144 N‑(4‑pentenyl) analogue)”;

(p)

in paragraph 21, after item (36), insert —

“(36AA)

2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3-methylbutanoic acid”; and

(q)

in paragraph 21, after item (54), insert —

“(54A)

4-{3-[(1-Adamantyl)carbamoyl]-1H-indazole-1-yl}butanoic acid”.

Amendment of Third Schedule

3. In Part 1 of the Third Schedule to the Misuse of Drugs Act 1973 —

(a)

in paragraph 1, after the item “1-Phenyl-2-propanone also known as Phenylacetone”, insert —

“N-Phenyl-N-(piperidin-4-yl)propionamide (also known as norfentanyl)

N-Phenylpiperidin-4-amine (also known as 4‑anilinopiperidine, N-phenyl-4-piperidinamine or 4‑AP)”;

(b)

in paragraph 1, in the item “Safrole also known as 4‑Allyl‑1,2‑methylenedioxybenzene”, delete the full‑stop at the end; and

(c)

in paragraph 1, after the item “Safrole also known as 4‑Allyl‑1,2‑methylenedioxybenzene”, insert —

“tert-Butyl 4-(phenylamino)piperidine-1‑carboxylate (also known as 4-anilino-1-boc-piperidine, 1‑boc‑4‑anilinopiperidine, tert-butoxycarbonyl-4-anilinopiperidine, t-boc-4-anilinopiperidine, t‑boc‑4‑AP, 1-boc-4-AP or boc-4-AP).”.

Made on 28 May 2022.

PANG KIN KEONG

Permanent Secretary,
Ministry of Home Affairs,
Singapore.

[MHA 112/2/0049; AG/LEGIS/SL/185/2020/6 Vol. 1]

Search within Legislation